欧盟 - 英文 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - e. coli adhesin f4 (f4ab, f4ac, f4ad), e. coli adhesin f5, e. coli adhesin f6, e. coli adhesin f41 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - sows; sows (nullipar) - reduction of neonatal enterotoxicosis of piglets, caused by e. coli strains, expressing the adhesins f4ab, f4ac, f4ad, f5, f6 and f41, during the first days of life.

欧盟 - 英文 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - afoxolaner - isoxazolines, ectoparasiticides for systemic use - dogs - treatment of flea infestation in dogs (ctenocephalides felis and c. canis)  for at least 5 weeks. the product can be used as part of a treatment strategy for the control of flea allergy dermatitis (fad).treatment of tick infestation in dogs (dermacentor reticulatus, ixodes ricinus, ixodes hexagonus, rhipicephalus sanguineus). one treatment kills ticks for up to one month.fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance. treatment of demodicosis (caused by demodex canis).treatment of sarcoptic mange (caused by sarcoptes scabiei var. canis).

欧盟 - 英文 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - afoxolaner, milbemycin oxime - endectocides, antiparasitic products, insecticides and repellents, milbemycin oxime, combinations - dogs - for the treatment of flea and tick infestations in dogs when the concurrent prevention of heartworm disease (dirofilaria immitis larvae), angiostrongylosis (reduction in level of immature adults (l5) and adults of angiostrongylus vasorum), thelaziosis (adult thelazia callipaeda) and/or treatment of gastrointestinal nematode infestations is indicated.treatment of flea infestations (ctenocephalides felis and c. canis) in dogs for 5 weeks. treatment of tick infestations (dermacentor reticulatus, ixodes ricinus, ixodes hexagonus, rhipicephalus sanguineus) in dogs for 4 weeks.fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.treatment of infestations with adult gastrointestinal nematodes of the following species: roundworms (toxocara canis and toxascaris leonina), hookworms (ancylostoma caninum, ancylostoma braziliense and ancylostoma ceylanicum) and whipworm (trichuris vulpis). treatment of demodicosis (caused by demodex canis). treatment of sarcoptic mange (caused by sarcoptes scabiei var. canis). prevention of heartworm disease (dirofilaria immitis larvae) with monthly administration. prevention of angiostrongylosis (by reduction of the level of infection with immature adult (l5) and adult stages of angiostrongylus vasorum) with monthly administration.prevention of establishment of thelaziosis (adult thelazia callipaeda eyeworm infection) with monthly administration.

欧盟 - 英文 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp1338 virus - immunostimulants, antineoplastic and immunomodulating agents, immunostimulants, - cats - immunotherapy to be used in association with surgery and radiotherapy in cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement, to reduce the risk of relapse and increase the time to relapse (local recurrence or metastasis).

欧盟 - 英文 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - firocoxib - anti-inflammatory and anti-rheumatic products, non-steroids - dogs - tabletsfor the relief of pain and inflammation associated with osteoarthritis in dogs.for the relief of postoperative pain and inflammation associated with soft-tissue, orthopaedic and dental surgery in dogs.oral pastealleviation of pain and inflammation associated with osteoarthritis and reduction of associated lameness in horses.

欧盟 - 英文 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - west nile recombinant canarypox virus (vcp2017 virus) - immunologicals for equidae, horse, immunologicals - horses - active immunisation of horses from five months of age against west nile disease by reducing the number of viraemic horses. if clinical signs are present, their duration and severity are reduced.

欧盟 - 英文 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - gamithromycin - antibacterials for systemic use - cattle; pigs; sheep - cattletreatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida and histophilus somni. the presence of the disease in the herd should be established before metaphylactic use.pigstreatment of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, haemophilus parasuis and bordetella bronchiseptica.sheeptreatment of infectious pododermatitis (foot rot) associated with virulent dichelobacter nodosus and fusobacterium necrophorum requiring systemic treatment.

欧盟 - 英文 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - chondrogenic induced equine allogeneic peripheral blood-derived mesenchymal stem cells - other drugs for disorders of the musculo-skeletal system - horses - reduction of mild to moderate recurrent lameness associated with non-septic joint inflammation in horses.

欧盟 - 英文 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - afoxolaner - ectoparasiticides for systemic use - dogs - treatment of flea (ctenocephalides felis and c. canis) infestations. the product can be used as part of a treatment strategy for the control of flea allergy dermatitis (fad). treatment of tick (dermacentor reticulatus, ixodes ricinus, rhipicephalus sanguineus) infestations. treatment of demodicosis (caused by demodex canis). treatment of sarcoptic mange (caused by sarcoptes scabiei var. canis).,

欧盟 - 英文 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease (md) virus, serotype 1, strain rn1250 - immunologicals for aves - chicken - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus).